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ABSTRACT
PiwiRNAs, small non-coding RNAs processed by Piwi proteins, are involved in 
maintaining genome stability in germline cells. Recently, piwiRNA expression has been 
identified in some tumors. We have examined the potential reactivation of the Piwi/
piwiRNA pathway in classical Hodgkin lymphoma (cHL). We found that Piwi proteins 
and three selected piwiRNAs, including piR-651, were expressed in cHL patients and 
cell lines, indicating that the Piwi/piwiRNA pathway is active in cHL. Interestingly, 
low levels of piR-651 were associated with lack of complete response to first-line 
treatment, as well as shorter disease-free and overall survival in a cohort of 94 cHL 
patients. At diagnosis, piR-651 was underexpressed in cHL serum samples compared 
to healthy controls, while after complete remission, piR-651 levels increased to levels 
similar to healthy controls. This is the first evidence that piwiRNAs are active in tumor 
and serum samples and impact prognosis in cHL.
INTRODUCTION
Classical Hodgkin lymphoma (cHL) comprises 11% 
of all lymphomas and is characterized by the presence of 
few tumoral cells, the so called Hodgkin Reed-Sternberg 
(HRS) cells, surrounded by a reactive microenvironment 
[1]. In cHL lymph nodes, the tumor bulk is mostly 
composed of T (CD4+ and cytotoxic T cells) and B cells, 
and macrophages and other cell types that crosstalk with 
the HRS cells through characteristic surface molecules 
expressed in both HRS cells and reactive cells and 
through secreted cytokyines and chemokines [2]. Most 
cHL patients can be cured using current treatment 
strategies. However, about 20% of the patients will die 
after relapse or progressive disease, indicating a need to 
identify prognostic markers that improve the International 
Prognostic score (IPS) [3, 4]. Several approaches to extend 
our knowledge of cHL biology and to identify prognostic 
biomarkers have been addressed, including the study of 
purified HRS cells [5], the study of the complete lymph 
node [6, 7] and the study of circulating biomarkers 
[8]. Recently, expression profiling of the complete 
lymph node identified a tumor-associated macrophage 
signature associated with outcome in cHL patients [9], 
demonstrating that the analysis of both tumor cells and 
the microenvironment can be an effective approach to 
understanding the behavior of cHL patients [10].
Non-coding RNAs have recently emerged as useful 
biomarkers, especially the small non-coding RNAs that 
are involved in post-transcriptional regulation mediated 
by Argonaute proteins. Argonaute proteins consist of 
two families: the Argonaute subfamily, which binds to 
microRNAs and siRNAs and the Piwi subfamily which 
binds exclusively to piwiRNAs (piRNAs) [11]. piRNAs 
are small non-coding RNAs (26-32nt), first discovered in 
2006 simultaneously by five groups as being expressed 
exclusively in mammalian testes [12–16]. piRNAs are 
generated by two different biogenesis pathways, known 
as the primary and secondary pathways (Supplementary 
Figure S1). In the primary pathway, after transcription the 
piRNA precursors are processed and transported to the 
cytoplasm where they are finally loaded onto Piwil1 and 
Piwil2 proteins. In the secondary pathway (also known as 
the “ping-pong” cycle), Piwil2 and Piwil4 bind in different 
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steps to piRNAs generated by the primary pathway. 
During the ping-pong cycle, the piRNA binds by sequence 
complementarity to a retrotransposon, producing at the 
end of the cycle the degradation of the target and a new 
copy of the piRNA [17]. This pathway, which depends on 
the abundance of both the specific piRNA and its target, 
leads to a selective amplification of piRNAs derived 
from active transposons. According to the latest update 
on piRNABank (2015) [18], a database which provides 
comprehensive information on piRNAs, more than 23,000 
piRNAs have been identified in humans. In adults, most 
of these piRNAs are only expressed in germline tissues, 
where they are crucial for fertility, as evidenced by the 
spermatogenesis defects observed in mice knockouts for 
Piwi proteins [19, 20]. In the germline, the key function 
of piRNAs is the repression of transposons, in order to 
prevent mutations caused by these mobile elements [21]. 
They regulate transposons at different levels, including the 
degradation of RNA [21] through the secondary pathway 
and the regulation of transposon expression by DNA 
methylation or histone modification [22]. Other functions 
have also been attributed to piRNAs, including the post-
transcriptional regulation of mRNAs [23].
Recently, piRNAs have been detected outside of 
germinal tissues [24], and interestingly, some of them are 
deregulated in tumor tissues. To date, only a few studies 
have analyzed the role of piRNAs in tumorogenesis and 
few piRNAs have been identified. piR-651, piR-4987, 
piR-20365, piR-20489, piR-20582, piR-932, piR-Hep1, 
and piR-823 have been shown to be upregulated in several 
tumors [25–28]; while only piR-823 has been described 
as downregulated [29]. However, the specific prognostic 
impact of piRNAs remains to be elucidated.
In the present work, we have investigated if the 
Piwi/piRNA pathway is active in cHL by studying the 
expression of Piwi proteins and the expression of selected 
piRNAs: piR-651, piR-20365 and piR-20582 [25, 26, 30]. 
We have found that the Piwi/piRNA pathway is indeed 
active in cHL and that the study of piRNAs can be a good 
source of prognostic markers.
RESULTS
Piwi/piRNA pathway is active in cHL
To investigate if the Piwi/piRNA pathway was 
active in cHL, we analyzed the expression of PIWIL1, 
PIWIL2 and PIWIL4 and that of piR-651, piR-20365 and 
piR-20582 [25, 26, 30].
PIWIL1, PIWIL2 and PIWIL4 showed different 
patterns of expression in the four cHL cell lines. PIWIL1 
was mostly expressed in L-1236 and HDLM2 (Figure 1A), 
while PIWIL2 and PIWIL4 were expressed in all four cell 
lines (Figure 1B–1C). When we compared the expression 
in the cell lines with those in B-cells from peripheral 
blood from healthy controls, we observed that PIWIL2 
and PIWIL4 were downregulated in the HL cell lines, but 
PIWIL1 was not expressed in the B-cells.
The immunohistochemical analysis of cHL patient 
samples showed that Piwil1 was expressed in only 5 of 
15 cases, exclusively in the cytoplasm of the HRS cells 
(Figure 2A–2B). In contrast, Piwil2 was detected in all 
the samples, both in the HRS cells and in the reactive 
microenvironment (Figure 2C–2D). Finally, Piwil4 was 
detected in 11 of 15 cases, only in the cytoplasm of the 
HRS cells (Figure 2E–2F).
All three piRNAs were expressed in all four cell 
lines and in all tumor samples (Figure 3). Moreover, 
piR-651 (p<0.0001) and piR-20582 (p=0.0003) were 
significantly upregulated in patient lymph nodes compared 
to RLN, while piR-20365 (p=0.0505) showed a trend to 
upregulation (Figure 3A–3C).
piR-651 and clinical outcome
Only piR-651 expression was associated with 
clinical outcome. Expression levels were dichotomized 
using the cutoff identified by MaxStat (cutoff=0.25; mean 
expression of low group:-0.046 [range:-0.37-0.18]; mean 
expression of high group: 1.27 [range: 0.26-6.11]). Low 
expression levels of piR-651 were associated with shorter 
DFS (Mean DFS: 83.3 vs. 197.9 months, p=0.0154) and 
shorter OS (Mean OS: 117.2 vs. 207.2 months; p=0.0218) 
(Figure 4A–4B). In the multivariate analysis, including all 
the individual clinical factors included in the International 
Prognostic Score(IPS) [3], low piR-651 emerged as an 
independent prognostic factor for DFS (OR, 4.21; 95% 
CI=1.342-13.209; p=0.014) and OS (OR, 2.836; 95% 
CI=1.042-7.717; p=0.041) (Table 1).
In the subset of 56 advanced-stage patients, piR-
651 retained its impact on both DFS (p=0.003) and OS 
(p=0.007), while the IPS was significant only in OS 
(p=0.04). In the multivariate analyses including the IPS 
score and piR-651, piR-651 emerged as an independent 
prognostic factor for both DFS (OR, 6.52; 95% CI=1.72-
24.77; p=0.006) and OS (OR, 2.92; 95% CI=1.07-7.93; 
p=0.036), while IPS was identified as a prognostic factor 
for OS (OR, 3.1; 95% CI=1.13-8.5; p=0.028).
piR-651 is associated with complete response
When patients were classified as responders or non-
responders to first-line treatment, non-responders had 
lower levels of piR-651 expression in lymph nodes (T-test 
p=0.0022) (Figure 4C). Using ROC curves to determine 
the capacity of piR-651 to distinguish responders vs non-
responders to first line treatment, we found that piR-651 
significantly discriminates between responders and non-
responders (AUC: 0.741, 95% CI 0.594-0.888; p=0.010). 
When piR-651 expression was analyzed as a dichotomous 
variable (cutoff: 0.25; sensitivity: 0.84; 1-specificity: 
0.45), lower levels of piR-651 were also associated with 
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treatment failure. Only 7.2% of patients with high piR-651 
expression had treatment failure, compared to 66.7% of 
those with low expression (Fisher’s Exact test, p=0.009).
Moreover, we performed a multivariate analysis 
including Age (≤45 vs >45), number of cycles of 
chemotherapy (≤4 vs >4), radiotherapy (Yes vs No), stage 
(I-II vs III-IV) and piR-651 (Low vs High). Low piR-651 
emerged as an independent prognostic factor for treatment 
failure (OR, 11.680; 95% CI=1.718-79.423; p=0.012) 
together with the ≤4 cycles of chemotherapy administered 
(OR, 11.761; 95% CI=1.497-92.406; p=0.019).
piR-651 levels in serum samples
When we studied piR-651 expression in prospectively 
collected serum samples, we observed that at diagnosis piR-
651 was underexpressed in cHL samples (n=11) compared 
to serum from healthy controls (n=10) (p=0.0137). 
Interestingly, after CR (n=9), piR-651 showed a trend to 
upregulation in serum in comparison to diagnostic samples 
(p=0.0594), reaching levels similar to those of healthy 
controls. At CR, no significant differences between patients 
and healthy controls were observed (p=0.296) (Figure 5).
piR-651 is expressed in HRS cells
To verify that the prognostic role of piR-651 was 
associated with its expression in HRS cells, we performed 
in situ hybridization analysis in lymph node tissue 
sections of four patients. piR-651 was expressed in normal 
follicles (Figure 6A) at low levels in the mantle cells and 
overexpressed in large centroblasts in the reactive germinal 
centers (Figure 6B). Moreover, piR-651 was highly 
expressed in the cytoplasm of HRS cells (Figure 6C–6D).
DISCUSSION
Small non-coding RNAs have emerged as 
important post-transcriptional regulators, especially 
siRNAs and microRNAs [31]. However, piRNAs have 
been understudied because until recently they were 
thought to be expressed exclusively in germinal tissues 
and early embryonic development and silenced in 
differentiated tissues [32]. However, recent findings on 
the detection of piRNAs in several tumors have shed 
light on the importance of this forgotten small non-
coding RNA group [30, 33]. In the present work, we have 
investigated whether the Piwi/piRNA pathway could 
be involved in the tumorogenesis process in cHL. We 
first studied PIWIL1, PIWIL2 and PIWIL4, which bind 
specifically to piRNAs and participate in their biogenesis 
[34]. The study of these genes in cHL cell lines showed 
two different expression patterns. PIWIL1 expression 
levels were very low in comparison to those of PIWIL2 
and PIWIL4. Moreover, PIWIL1 expression was only 
detected at significant levels in one of four cHL cell lines. 
In contrast, PIWIL2 and PIWIL4 were expressed in all 
four cHL cell lines. This difference may be due to their 
participation in the two different biogenesis pathways 
[35]. PIWIL1 acts exclusively in the primary biogenesis 
pathway, while PIWIL4 is active only in the secondary 
pathway and PIWIL2 acts in both. The differences in 
Figure 1: PIWIL1, PIWIL2 and PIWIL4 expression in cHL. PIWIL1 A. PIWIL2 B. and PIWIL4 C. mRNA expression in four 
cHL cell lines. PIWIL2-4 were showed as RQ calibrated with the expression of peripheral blood B-cells, while PIWIL1 was showed in 
2-ΔCt since it is not expressed in B-cells. The graph shows the median and SEM of three technical replicates. Western blot for PIWIL1 
D. PIWIL2 E. and PIWIL4 F. in HL cell lines.
Oncotarget46005www.impactjournals.com/oncotarget
Figure 2: Immunohistochemistry of protein expression of Piwil1 A, B. Piwil2 C, D. and Piwil4 E, F. in patient lymph nodes. 
Arrows indicate representative HRS cells.
Figure 3: Expression levels of three selected piRNAs. Expression levels of piR-651 A. piR-20365 B. and piR-20582 C. in 94 cHL 
lymph nodes, 12 reactive lymph nodes (RLN) and four cHL cell lines.
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PIWIL1 expression in the different cell lines may thus 
indicate that the primary pathway is not always active. 
The primary pathway is in charge of generating new 
piRNA sequences, while the secondary pathway helps 
to maintain the existent piRNA pool in the cell [35]. 
Interestingly, in several solid tumors, the reactivation 
of PIWIL1 expression, associated with worse prognosis, 
could be related to a stem cell phenotype [36–39]. 
Similarly, PIWIL1 is expressed in CD34+ hematopoietic 
stem cells [40]. When we studied Piwi protein expression 
in patient lymph nodes, we observed a similar pattern 
to that in cell lines. Piwil1 was only detected in the 
cytoplasm of tumor cells in few cases, while Piwil2 and 
Piwil4 were detected in most of the cases. Moreover, 
Piwil2 expression was not exclusive to HRS cells but 
was also detected in most of the microenvironment cells, 
indicating that the secondary pathway is not exclusive 
to tumor cells. Along these same lines, PIWIL2 and 
PIWIL4 have been detected in other tumors as well in 
their normal counterpart [36, 41].
Figure 4: PiR-651 impacts outcome in cHL patients. Disease-free survival A. and overall survival B. according to piR-651 levels. 
C. piR-651 levels according to response to first-line treatment (Treatment failure vs Complete response).
Table 1: Multivariate analyses
Disease-Free Survival Odds Ratio (95% CI) P
  Male sex 2.855 (0.887-9.187) 0.078
  Age>45 years 2.478 (0.579-10.612) 0.221
  Stage III-IV 1.320 (0.324-5.381) 0.699
  Hemoglobin <105 g/L 8.458 (0.974-73.450) 0.053
Albumin <40g/L 3.274 (1.058-10.136) 0.040
  White-cell count >15,000/mm3 2.113 (0.413-10.808) 0.369
  Lymphocyte count <600/mm3 or <8% <0.001 (<0.001-<0.001) 0.986
Low piR-651 expression 4.210 (1.342-13.209) 0.014
Overall Survival Odds Ratio (95% CI) P
  Male sex 1.535 (0.564-4.177) 0.402
Age>45 years 13.681 (4.281-43.726) <0.0001
  Stage III-IV 2.107 (0.583-7.620) 0.256
  Hemoglobin <105 g/L 0.820 (0.259-2.598) 0.736
  Albumin <40g/L 2.828 (0.996-8.032) 0.051
White-cell count > 15,000/mm3 4.282 (1.332-13.762) 0.015
  Lymphocyte count <600/mm3 or <8% 2.782 (0.810-9.553) 0.104
Low piR-651 expression 2.836 (1.042-7.717) 0.041
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To further explore the activity of the Piwi/piRNA 
pathway in cHL, we investigated if three piRNAs (piR-
651, piR-20365, piR-20582) that had previously been 
identified as overexpressed in solid tumors [25, 26] could 
be detected in cHL. The three piRNAs were detected in 
all the samples, including lymph nodes from cHL patients, 
reactive lymph nodes used as controls, and the four cHL 
cell lines. The detection of the piRNAs in control samples 
indicated that probably a piRNA pool is maintained in 
somatic tissues [32, 33], including lymph nodes.
In fact, the study by in situ hybridization of piR-651 
showed that it was expressed not only in HRS cells but also 
in normal follicles, especially at centroblasts. Interestingly, 
piR-651 expression in patient lymph nodes was significantly 
higher than in RLN suggesting that this upregulation is due 
to the presence of the population of HRS cells, which are 
expressing piR-651 and at the same time producing changes 
in the surrounding cells that lead to an increase of global 
piR-651 levels in the HL lymph node.
As previously found in other tumors [25, 26], the 
three piRNAs were overexpressed in the tumor samples.
We then examined the potential correlation of the 
expression of these piRNAs in lymph node samples with 
patient outcome and found that piR-651 emerged as an 
independent prognostic marker for DFS and OS. The 
patients with low levels of piR-651 had worse outcome. 
Remarkably, patients that did not achieve treatment 
response had lower levels of piR-651.
In the same line, the analysis of piR-651 in serum 
samples showed that piR-651 levels were downregulated 
at diagnosis but increased after treatment when the patient 
achieved CR. Cui et al. showed that piR-651 analyzed in 
mononuclear cells from peripheral blood from gastric 
cancer patients was also lower in comparison with control 
samples [42]. This leads us to speculate that the expression 
of piR-651 detected in serum could come from circulating 
cells rather than from tumor cells and the downregulation 
observed in the patients could reflect differences in the 
peripheral blood populations associated to the presence of 
the lymphoma. It has previously been reported that immune 
suppression associated with the lymphoma pathogenesis 
may be found systemically resulting from an altered 
monocyte phenotype in patients with lymphoma [43].
Similar results have been observed when studying 
serum expression of microRNAs in other tumors, 
including multiple myeloma, where several miRNAs were 
underexpressed in serum at diagnosis but increased at CR, 
and lower levels in serum were associated with shorter 
progression-free survival [44]. In cHL, only one previous 
study has examined microRNAs in plasma samples, and 
the authors identified several microRNAs, including miR-
494 and miR-1973, whose levels were upregulated at 
diagnosis and decreased at CR [8]. This is in line with our 
results and indicates that the analysis of small non-coding 
RNAs in serum/plasma samples could be useful to monitor 
treatment response.
Figure 5: PiR-651 levels in serum samples. PiR-651 was studied in serum samples from healthy controls and from cHL patients 
prospectively collected. From cHL patients paired samples at diagnosis and at CR after first line treatment were included.
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Contrary to our results, piR-651 was identified as an 
oncogene in gastric cancer, where Cheng and coworkers 
demonstrated in vitro that the inhibition of piR-651 was 
associated with a decrease in cell growth due to an arrest 
in G2/M phase of gastric cancer cell lines [25]. In contrast, 
though we have also observed overexpression of piR-651 
in patient samples in comparison with RLN, low levels 
of piR-651 were associated with worse patient outcome. 
It has previously been demonstrated that other small non-
coding RNAs, such as microRNAs, can play a dual role 
as an oncogene or a tumor suppressor gene according 
to the cellular context [45]. Treatment has been shown 
to produce changes in the cellular context affecting the 
function of some microRNAs, which become oncogenes 
or tumor suppressor genes when treatment is administered 
by a target-dependent mechanism [46]. Like microRNAs, 
piRNAs are involved in post-transcriptional regulation 
through a similar mechanism based on targeting RNAs by 
base pairing between complementary sequences that leads 
to translational repression [23]. To date, only a few studies 
have associated piRNAs and cancer, most of which have 
shown that piRNAs are overexpressed and act as oncogenes 
[25–29, 41, 47]. However, piRNAs can also play a dual role 
depending on the tumor. For example, piR-823 has been 
shown to act as a tumor suppressor in gastric cancer [29] 
and as an oncogene in multiple myeloma [28].
In summary, we show here for the first time that 
the Piwi/piRNA pathway is active in cHL. Moreover, we 
have identified a piR-651 as a potential biomarker that 
can be detected in serum. piR-651 may act as a tumor 
Figure 6: In situ hybridization of piR-651. Arrows indicate representative HRS cells. A. piR-651 was expressed in normal follicles 
at low levels in the mantle cells and B. overexpressed in large centroblasts in the reactive germinal centers. C-D. piR-651 was highly 
expressed in the cytoplasm of HRS cells. E-F. negative control.
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suppressor since patients with low piR-651 levels had 
shorter OS, associated with worse response to first-line 
treatment. Interestingly, piR-651 levels in serum increase 
at response to treatment. Further investigation in a larger 
cohort of patients is warranted to confirm these findings 
and to further validate the potential importance of piR-651 
as a prognostic marker in cHL.
MATERIALS AND METHODS
Patients
Ninety-four patients diagnosed with cHL at a single 
institution between February 1994 and December 2010 
were included in the analysis. The only exclusion criterion 
was HIV+. Median age was 38 years, and 48% were male. 
The most frequent histological subtypes were nodular 
sclerosis (65%) and mixed cellularity (19%). Using criteria 
previously described [7], we found that Epstein-Barr virus 
was present in 30% of the samples. The most frequent 
first-line treatments were ABVD (62%) and MOPPABV 
(29%). After first-line treatment, 76 patients (81%) 
achieved complete remission, two (2%) partial remission, 
and 11 (11.7%) treatment failure, while five patients 
(5.3%) died before response evaluation (Table 2). With 
a median follow-up of 133.5 months (range, 2.8-244.1 
months), overall survival was 78.7%. Twelve reactive 
lymph nodes were used as controls. Serum samples from 
eleven prospectively collected cHL patients at diagnosis 
and nine paired samples at complete response and from 
10 healthy controls were used to study the expression of 
piRNAs in serum. Approval for this study was obtained 
from the Institutional Review Board of Hospital Clinic, 
Barcelona. Informed consent was obtained in accordance 
with the Declaration of Helsinki.
Cell culture
Four cHL cell lines were used: L-428, L-1236, 
L-540 and HDLM2 (DSMZ - the German Resource Centre 
for Biological Material). The cell lines used were obtained 
from DSMZ at the beginning of the current work and 
tested for mycoplasma contamination at least once time at 
month. The L-428 and L-1236 cell lines were cultured in 
RPMI 1640 containing 10% fetal calf serum (Invitrogen, 
Paisley, UK); the L-540 and HDLM2 cell lines were 
cultured in RPMI 1640 containing 20% fetal bovine serum 
(Invitrogen).
RNA extraction
Total RNA was obtained from formalin-fixed 
paraffin-embedded (FFPE) lymph nodes as previously 
described [6, 7] using RecoverAll Total Nucleic Acid 
Isolation Kit (Life Technologies, Foster City, CA). All 
patient lymph nodes were obtained at diagnosis. Total 
RNA from cHL cell lines was extracted using Trizol (Life 
Technologies) according to the manufacturer’s protocol. 
RNA concentration was obtained using NanoDrop ND-
1000 Spectrophotometer (Fisher Scientific, Madrid, 
Spain).
Table 2: Demographic and clinical characteristics of 
cHL patients (N=94)
Variable N (%)
Median age, yrs (range) 34 (15–89)
 ≤45 68 (72.3)
 >45 26 (27.7)
Male sex 45 (47.9)
Histologic subtype
 Nodular sclerosis 61 (64.9)
 Mixed cellularity 18 (19.2)
 Lymphocyte-rich 6 (6.4)
 Lymphocyte-depleted 2 (2.1)
 Not classifiable 7 (7.4)
Stage
 I 6 (6.4)
 II 51 (54.3)
 III 18 (19.1)
 IV 19 (20.2)
Presence of B symptoms 38 (40.4)
Presence of Bulky mass 21 (22.3)
Hemoglobin <105 g/L 19 (20.2)
Albumin <40g/L 54 (57.4)
White-cell count > 15,000/mm3 13 (13.8)
Lymphocyte count <600/mm3 or <8% 11 (11.7)
EBV
 Positive 28 (29.8)
 Negative 49 (52.1)
 Unknown 17 (18.1)
First-line treatment
 ABVD1 58 (61.7)
 MOPPABV2 27 (28.7)
 MOPP3 4 (4.3)
 Other 5 (5.3)
1Twenty patients received ABVD with radiation;
2Fourteen patients received MOPPABV with radiation;
3One patient received MOPP with radiation.
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mRNA quantification
cDNA was synthesized from total RNA using 
the High Capacity cDNA Reverse Transcription Kit 
(Life Technologies) as per the manufacturer’s protocol. 
TaqMan expression assays to determine mRNA levels of 
PIWIL1 (Hs01041737_m1), PIWIL2 (Hs00216263_m1) 
and PIWIL4 (Hs00381509_m1) were supplied by Life 
Technologies. β-actin was used as housekeeping gene. RT-
QPCR was performed in a total volume of 20 μl in the ABI 
Prism 7500 Real Time PCR System (Life Technologies). 
All samples for each gene were run in triplicate for 40 
cycles using the following master mix and thermal cycler 
conditions: 10 μl of the TaqMan universal PCR master 
mix, 1 μl of the primers and probes, 2 μl of the cDNA 
and 7 μl of the RNAse-free water; about 2 min 50 °C, 
10 min 95 °C, 15 s 95 °C and 1 min 60 °C. Fluorescent 
emission data was captured, and mRNA concentrations 
were quantified by using the critical threshold value and 
2−ΔΔCt method.
Western blot
Western Blot analysis was performed as previously 
described [48] using the following primary antibodies: 
PIWIL1 (ab85125; Abcam, Cambridge, UK), PIWIL2 
(ab98852; Abcam) and PIWIL4 (ab111714; Abcam) and 
α-tubulin (A9044; Sigma).
Immunohistochemistry
Five-μm-thick transverse sections of FFPE tissues 
were serially cut and mounted onto Dako Silanized Slides 
(Dako, Glostrup, Denmark). The immunohistochemical 
assay was performed as previously described [49] using 
rabbit polyclonal antibodies anti-human PIWIL1 (ab85125; 
Abcam), PIWIL2 (ab98852; Abcam) and PIWIL4 (NBP1-
83491; Novus Biologicals, Littleton, CO, USA).
piRNA expression analysis
To quantify piRNA expression, we made cDNA 
using miScript II RT Kit (Qiagen) as follows: 2 μl of 5x 
miScript HiSpec Buffer, 1 μl of 10x miScript Nucleics 
Mix, 1 μl of miScript Rerverse Transcriptase Mix and 250 
ng of RNA in 6 μl of distilled water. This was incubated 
for 1 hour at 37º and 5 minutes at 95º. The cDNA was then 
used for RT-QPCR quantification of piRNA expression 
using miScript SYBR Green PCR Kit (Qiagen). For 
the RT-QPCR, the universal primer included in the kit 
was used together with the following primers: piR-651 
(5’-AGAGAGGGGCCCGTGCCTTG-3’) [25], piR-20365 
(5’-GGCCGTGATCGTATAGTGGTTAGT-3’), piR-20582 
(5’-GGTGTAATGGTTAGCACTCTG-3’). RT-QPCR was 
performed on 7500 Real time PCR (Applied Biosytems). 
For each sample: 5 μl of 2x QuantiTect SYBR Green PCR 
Master Mix, 1 μl of 10x miScript Universal Primer, 1 μl 
of the specific primer (10nM), 2 μl of distilled water and 
1 μl of our cDNA template. PCR conditions were: first 15 
minutes at 95ºC, followed by 40 cycles of 15s at 94ºC, 30s 
at 55ºC and 34s at 70ºC, and finally the dissociation curve 
analysis. RNU6B (Hs_RNU6-2_11, Qiagen miScript 
Primer Assays) was used as endogenous control.
PiRNA expression analysis in serum samples
Total RNA from serum samples was obtained as 
previously described [44] using miRNeasy Mini Kit 
(Qiagen). The quantification of piR-651 levels were 
performed using the same methodology than in lymph 
nodes (previous section) but for cDNA synthesis only 
100ng of total RNA was used.
Chromogenic in situ hybridization
Custom miRCURY LNA Detection Probe (Exiqon 
A/S, Vedbaek, Denmark) 5’ fluorescein labelled for piR-
651 was used in FFPE tissue sections on Dako Silanized 
Slides (S·3003; Dako). Chromogenic in situ hybridization 
was performed manually. For dewaxing and antigen 
retrieval, the sections were manually immersed in Target 
Retrieval solution, high pH (Dako) and heated in a water 
bath at 95–99°C for 20 min (Dako PT Link). Slides were 
pretreated with protease 1 for 15 minutes at 37°C. A 
total amount of 70μl of 25-nM probe was hybridized in 
1X sodium chloride–sodium citrate hybridization buffer 
(SSC) (Innogenetics, Antwerp, Belgium) up to 52°C for 
2 hours. We used a prediluted mouse anti-FITC antibody 
(Leica Biosystems, Nußloch, Alemania) for 60 minutes. 
Immunoperoxidase staining was performed using Advance 
system/HRP (Dako) and Liquid DAB+ (Dako). Finally, 
sections were stained with hematoxylin.
Statistical analyses
We analyzed the association of piRNA expression 
with disease-free survival (DFS), overall survival (OS) 
and complete response (CR). DFS was measured from the 
time of occurrence of a disease-free state or attainment of a 
CR to disease recurrence or death as a result of lymphoma 
or acute toxicity of treatment. OS was calculated from the 
time of diagnosis to the date of death from any cause or last 
follow-up. Optimal cut-offs of piRNA expression data for 
DFS and OS were assessed by means of maximally selected 
log-rank statistics using the Maxstat package (R statistical 
package, v. 2.8.1, Vienna, Austria) [50]. MaxStat identified 
a significant cutoff only for piR-651(cutoff=0.25; mean 
expression of low group:-0.046 [range:-0.37-0.18]; mean 
expression of high group: 1.27 [range: 0.26-6.11]).
DFS and OS were estimated with the Kaplan-Meier 
method and compared with the log-rank test. A multivariate 
regression analysis assessing the significance of individual 
clinical factors included in the International Prognostic 
Score and significant piRNAs was performed by using the 
Oncotarget46011www.impactjournals.com/oncotarget
Cox proportional hazards model with backward selection. 
The Chi-squared or Fisher’s exact test was used to estimate 
differences in distributions. The multivariate analysis for 
treatment response was performed by using Binary Logistic 
regression. All statistical analyses were performed using 
PAS W Statistics 18 (SPSS Inc., Chicago, IL) and R v2.8.1. 
The level of significance was set at ≤0.05. All performed 
tests were two-sided.
CONFLICTS OF INTEREST
All authors declare no conflicts of interest.
GRANT SUPPORT
This work was supported by grants from AECC-
Catalunya 2013 (sponsored by Mat Holding) and SDCSD 
of University of Barcelona. A.C. and J.J.C. are APIF 
fellows of the University of Barcelona and M.D.B. is 
supported by ISCII (Rio Hortega CM13/00205).
REFERENCES
1. Küppers R. Molecular biology of Hodgkin lymphoma. ASH 
Education Program Book. 2009; 2009:491-496.
2. Greaves P, Clear A, Owen A, Iqbal S, Lee A, Matthews 
J, Wilson A, Calaminici M and Gribben JG. Defining 
characteristics of classical Hodgkin lymphoma 
microenvironment T-helper cells. Blood. 2013; 
122:2856-2863.
3. Hasenclever D, Diehl V, Armitage JO, Assouline D, Björkholm 
M, Brusamolino E, Canellos GP, Carde P, Crowther D 
and Cunningham D. A prognostic score for advanced 
Hodgkin’s disease. New England Journal of Medicine. 1998; 
339:1506-1514.
4. Connors JM. Risk assessment in the management of newly 
diagnosed classical Hodgkin lymphoma. Blood. 2015; 
125:1693-1702.
5. Tiacci E, Döring C, Brune V, van Noesel CJ, Klapper W, 
Mechtersheimer G, Falini B, Küppers R and Hansmann 
M-L. Analyzing primary Hodgkin and Reed-Sternberg 
cells to capture the molecular and cellular pathogenesis of 
classical Hodgkin lymphoma. Blood. 2012; 120:4609-4620.
6. Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel 
B, Codony C, Ferrer G, Martinez C and Montserrat E. 
Regulation of JAK2 by miR-135a: prognostic impact in 
classic Hodgkin lymphoma. Blood. 2009; 114:2945-2951.
7. Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons 
A, Balagué O, Gel B, Abrisqueta P, Lopez-Guillermo A 
and Artells R. MicroRNA expression profiling in classic 
Hodgkin lymphoma. Blood. 2008; 111:2825-2832.
8. Jones K, Nourse JP, Keane C, Bhatnagar A and Gandhi 
MK. Plasma microRNA are disease response biomarkers 
in classical Hodgkin lymphoma. Clinical Cancer Research. 
2014; 20:253-264.
9. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, 
Delaney A, Jones SJ, Iqbal J and Weisenburger DD. Tumor-
associated macrophages and survival in classic Hodgkin’s 
lymphoma. New England Journal of Medicine. 2010; 
362:875-885.
10. Steidl C, Connors JM and Gascoyne RD. Molecular 
pathogenesis of Hodgkin’s lymphoma: increasing evidence 
of the importance of the microenvironment. Journal of 
Clinical Oncology. 2011; 29:1812-1826.
11. Hutvagner G and Simard MJ. Argonaute proteins: key 
players in RNA silencing. Nature reviews Molecular cell 
biology. 2008; 9:22-32.
12. Watanabe T, Takeda A, Tsukiyama T, Mise K, Okuno 
T, Sasaki H, Minami N and Imai H. Identification and 
characterization of two novel classes of small RNAs in 
the mouse germline: retrotransposon-derived siRNAs 
in oocytes and germline small RNAs in testes. Genes & 
development. 2006; 20:1732-1743.
13. Grivna ST, Beyret E, Wang Z and Lin H. A novel class 
of small RNAs in mouse spermatogenic cells. Genes & 
development. 2006; 20:1709-1714.
14. Girard A, Sachidanandam R, Hannon GJ and Carmell MA. 
A germline-specific class of small RNAs binds mammalian 
Piwi proteins. Nature. 2006; 442:199-202.
15. Aravin A, Gaidatzis D, Pfeffer S, Lagos-Quintana 
M, Landgraf P, Iovino N, Morris P, Brownstein MJ, 
Kuramochi-Miyagawa S and Nakano T. A novel class 
of small RNAs bind to MILI protein in mouse testes. 
Nature. 2006; 442:203-207.
16. Lau NC, Seto AG, Kim J, Kuramochi-Miyagawa S, 
Nakano T, Bartel DP and Kingston RE. Characterization 
of the piRNA complex from rat testes. Science. 2006; 
313:363-367.
17. Grimson A, Srivastava M, Fahey B, Woodcroft BJ, Chiang 
HR, King N, Degnan BM, Rokhsar DS and Bartel DP. Early 
origins and evolution of microRNAs and Piwi-interacting 
RNAs in animals. Nature. 2008; 455:1193-1197.
18. Lakshmi SS and Agrawal S. piRNABank: a web resource 
on classified and clustered Piwi-interacting RNAs. Nucleic 
acids research. 2008; 36:D173-D177.
19. Deng W and Lin H. Miwi, a murine homolog of piwi, 
encodes a cytoplasmic protein essential for spermatogenesis. 
Developmental cell. 2002; 2:819-830.
20. Kuramochi-Miyagawa S, Kimura T, Ijiri TW, Isobe T, 
Asada N, Fujita Y, Ikawa M, Iwai N, Okabe M and Deng W. 
Mili, a mammalian member of piwi family gene, is essential 
for spermatogenesis. Development. 2004; 131:839-849.
21. Brennecke J, Aravin AA, Stark A, Dus M, Kellis M, 
Sachidanandam R and Hannon GJ. Discrete small RNA-
generating loci as master regulators of transposon activity 
in Drosophila. Cell. 2007; 128:1089-1103.
Oncotarget46012www.impactjournals.com/oncotarget
22. Castel SE and Martienssen RA. RNA interference in the 
nucleus: roles for small RNAs in transcription, epigenetics 
and beyond. Nature Reviews Genetics. 2013; 14:100-112.
23. Watanabe T and Lin H. Posttranscriptional Regulation of 
Gene Expression by Piwi Proteins and piRNAs. Molecular 
cell. 2014; 56:18-27.
24. Rajasethupathy P, Antonov I, Sheridan R, Frey S, Sander C, 
Tuschl T and Kandel ER. A role for neuronal piRNAs in 
the epigenetic control of memory-related synaptic plasticity. 
Cell. 2012; 149:693-707.
25. Cheng J, Guo J-M, Xiao B-X, Miao Y, Jiang Z, Zhou H and 
Li Q-N. piRNA, the new non-coding RNA, is aberrantly 
expressed in human cancer cells. Clinica Chimica Acta. 
2011; 412:1621-1625.
26. Huang G-l, Hu H, Xue X, Shen S, Gao E-l, Guo G, Shen 
X and Zhang X. Altered expression of piRNAs and their 
relation with clinicopathologic features of breast cancer. 
Clinical and Translational Oncology. 2013; 15:563-568.
27. Law PT-Y, Qin H, Ching AK-K, Lai KP, Co NN, He M, 
Lung RW-M, Chan AW-H, Chan T-F and Wong N. Deep 
sequencing of small RNA transcriptome reveals novel 
non-coding RNAs in hepatocellular carcinoma. Journal of 
hepatology. 2013; 58:1165-1173.
28. Yan H, Wu Q, Sun C, Ai L, Deng J, Zhang L, Chen L, 
Chu Z, Tang B and Wang K. piRNA-823 contributes to 
tumorigenesis by regulating de novo DNA methylation 
and angiogenesis in multiple myeloma. Leukemia. 2015; 
29:196-206. doi: 10.1038/leu.2014.135.
29. Cheng J, Deng H, Xiao B, Zhou H, Zhou F, Shen Z and Guo J. 
piR-823, a novel non-coding small RNA, demonstrates in 
vitro and in vivo tumor suppressive activity in human gastric 
cancer cells. Cancer letters. 2012; 315:12-17.
30. Mei Y, Clark D and Mao L. Novel dimensions of piRNAs 
in cancer. Cancer letters. 2013; 336:46-52.
31. Esteller M. Non-coding RNAs in human disease. Nature 
Reviews Genetics. 2011; 12:861-874.
32. Ross RJ, Weiner MM and Lin H. PIWI proteins and PIWI-
interacting RNAs in the soma. Nature. 2014; 505:353-359.
33. Ishizu H, Siomi H and Siomi MC. Biology of PIWI-
interacting RNAs: new insights into biogenesis and function 
inside and outside of germlines. Genes & development. 
2012; 26:2361-2373.
34. Suzuki R, Honda S and Kirino Y. PIWI expression and 
function in cancer. Frontiers in genetics. 2012; 3.
35. Luteijn MJ and Ketting RF. PIWI-interacting RNAs: from 
generation to transgenerational epigenetics. Nature Reviews 
Genetics. 2013; 14:523-534.
36. Navarro A, Tejero R, Viñolas N, Cordeiro A, Marrades R, Fuster 
D, Caritg O, Moises J, Muñoz C and Molins L. The significance 
of PIWI family expression in human lung embryogenesis and 
non-small cell lung cancer. Oncotarget. 2015; 6:31544-56. 
doi: 10.18632/oncotarget.3003.
37. Zhao YM, Zhou JM, Wang LR, He HW, Wang XL, Tao ZH, 
Sun HC, Wu WZ, Fan J and Tang ZY. HIWI is associated 
with prognosis in patients with hepatocellular carcinoma 
after curative resection. Cancer. 2012; 118:2708-2717.
38. Taubert H, Greither T, Kaushal D, Würl P, Bache M, Bartel 
F, Kehlen A, Lautenschläger C, Harris L and Kraemer K. 
Expression of the stem cell self-renewal gene Hiwi and risk 
of tumour-related death in patients with soft-tissue sarcoma. 
Oncogene. 2007; 26:1098-1100.
39. Grochola L, Greither T, Taubert H, Möller P, Knippschild U, 
Udelnow A, Henne-Bruns D and Würl P. The stem cell-
associated Hiwi gene in human adenocarcinoma of the 
pancreas: expression and risk of tumour-related death. 
British journal of cancer. 2008; 99:1083-1088.
40. Fujita K, Tsujimura A, Miyagawa Y, Kiuchi H, Matsuoka 
Y, Takao T, Takada S, Nonomura N and Okuyama A. 
Isolation of germ cells from leukemia and lymphoma cells 
in a human in vitro model: potential clinical application for 
restoring human fertility after anticancer therapy. Cancer 
research. 2006; 66:11166-11171.
41. Zhang H, Ren Y, Xu H, Pang D, Duan C and Liu C. The 
expression of stem cell protein Piwil2 and piR-932 in breast 
cancer. Surgical oncology. 2013; 22:217-223.
42. Cui L, Lou Y, Zhang X, Zhou H, Deng H, Song H, Yu X, 
Xiao B, Wang W and Guo J. Detection of circulating tumor 
cells in peripheral blood from patients with gastric cancer 
using piRNAs as markers. Clinical biochemistry. 2011; 
44:1050-1057.
43. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE 
and Dietz AB. Immunosuppressive CD14+ HLA-DRlow/− 
monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011; 
117:872-881.
44. Navarro A, Díaz T, Tovar N, Pedrosa F, Tejero R, Cibeira 
M, Magnano L, Rosiñol L, Monzó M and Bladé J. A serum 
microRNA signature associated with complete remission 
and progression after autologous stem-cell transplantation 
in patients with multiple myeloma. Oncotarget. 2015; 
6:1874-83. doi: 10.18632/oncotarget.2761.
45. Schotte D, Pieters R and Den Boer M. MicroRNAs in acute 
leukemia: from biological players to clinical contributors. 
Leukemia. 2012; 26:1-12.
46. Li H and Yang BB. Friend or foe: the role of microRNA 
in chemotherapy resistance. Acta Pharmacologica Sinica. 
2013; 34:870-879.
47. Lu YL and Zhang K. Identification of piRNAs in Hela 
cells by massive parallel sequencing. Biochemistry and 
Molecular Biology Reports. 2010; 43:635-641.
48. Diaz T, Navarro A, Ferrer G, Gel B, Gaya A, Artells R, 
Bellosillo B, Garcia-Garcia M, Serrano S and Martínez A. 
Lestaurtinib inhibition of the Jak/STAT signaling pathway 
in hodgkin lymphoma inhibits proliferation and induces 
apoptosis. PloS one. 2011; 6:e18856.
Oncotarget46013www.impactjournals.com/oncotarget
49. Artells R, Navarro A, Diaz T and Monzó M. Ultrastructural and 
Immunohistochemical Analysis of Intestinal Myofibroblasts 
During the Early Organogenesis of the Human Small Intestine. 
The Anatomical Record. 2011; 294:462-471.
50. Hothorn T and Lausen B. On the exact distribution of 
maximally selected rank statistics. Computational Statistics 
& Data Analysis. 2003; 43:121-137
